EDIT vs. PACB

Last updated Apr 1, 2026

Compare and contrast key facts about Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB).

Performance

EDIT vs. PACB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). The values are adjusted to include any dividend payments, if applicable.

EDIT vs. PACB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EDIT Editas Medicine, Inc.	20.49%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%
PACB Pacific Biosciences of California, Inc.	-29.41%	2.19%	-81.35%	19.93%	-60.02%	-21.13%	404.67%	-30.54%	180.30%	-30.53%

Fundamentals

Market Cap EDIT : $219.20M PACB : $398.52M
EPS EDIT : -$1.82 PACB : -$1.82
PS Ratio EDIT : 5.35 PACB : 2.48
PB Ratio EDIT : 8.03 PACB : 74.50
Total Revenue (TTM) EDIT : $40.52M PACB : $160.01M
Gross Profit (TTM) EDIT : $39.72M PACB : $50.67M
EBITDA (TTM) EDIT : $0.00 PACB : -$161.03M

Returns By Period

In the year-to-date period, EDIT achieves a 20.49% return, which is significantly higher than PACB's -29.41% return. Over the past 10 years, EDIT has underperformed PACB with an annualized return of -23.69%, while PACB has yielded a comparatively higher -17.78% annualized return.

EDIT

• 1D: 10.76%
• 1M: 12.27%
• YTD: 20.49%
• 6M: -28.82%
• 1Y: 112.93%
• 3Y*: -30.16%
• 5Y*: -43.48%
• 10Y*: -23.69%

PACB

• 1D: 4.76%
• 1M: -21.43%
• YTD: -29.41%
• 6M: 3.13%
• 1Y: 11.86%
• 3Y*: -51.51%
• 5Y*: -47.73%
• 10Y*: -17.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

EDIT vs. PACB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT

EDIT Risk / Return Rank: 75
EDIT Sharpe Ratio Rank: 78
EDIT Sortino Ratio Rank: 82
EDIT Omega Ratio Rank: 75
EDIT Calmar Ratio Rank: 73
EDIT Martin Ratio Rank: 68

PACB

PACB Risk / Return Rank: 50
PACB Sharpe Ratio Rank: 47
PACB Sortino Ratio Rank: 55
PACB Omega Ratio Rank: 49
PACB Calmar Ratio Rank: 49
PACB Martin Ratio Rank: 49

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EDIT vs. PACB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EDIT	PACB	Difference
Sharpe ratio Return per unit of total volatility	1.16	0.13	+1.03
Sortino ratio Return per unit of downside risk	2.16	0.96	+1.20
Omega ratio Gain probability vs. loss probability	1.24	1.10	+0.14
Calmar ratio Return relative to maximum drawdown	1.63	0.30	+1.33
Martin ratio Return relative to average drawdown	3.10	0.63	+2.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

EDIT vs. PACB - Sharpe Ratio Comparison

The current EDIT Sharpe Ratio is 1.16, which is higher than the PACB Sharpe Ratio of 0.13. The chart below compares the historical Sharpe Ratios of EDIT and PACB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	EDIT	PACB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.16	0.13	+1.03
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.47	-0.51	+0.04
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.28	-0.21	-0.07
Sharpe Ratio (All Time) Calculated using the full available price history	-0.21	-0.18	-0.03

Correlation

The correlation between EDIT and PACB is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

EDIT vs. PACB - Dividend Comparison

Neither EDIT nor PACB has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EDIT vs. PACB - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, roughly equal to the maximum PACB drawdown of -98.22%. Use the drawdown chart below to compare losses from any high point for EDIT and PACB.

Drawdown Indicators

	EDIT	PACB	Difference
Max Drawdown Largest peak-to-trough decline	-98.92%	-98.22%	-0.70%
Max Drawdown (1Y) Largest decline over 1 year	-59.88%	-52.81%	-7.07%
Max Drawdown (5Y) Largest decline over 5 years	-98.66%	-97.47%	-1.19%
Max Drawdown (10Y) Largest decline over 10 years	-98.92%	-98.22%	-0.70%
Current Drawdown Current decline from peak	-97.27%	-97.42%	+0.15%
Average Drawdown Average peak-to-trough decline	-61.98%	-70.20%	+8.22%
Ulcer Index Depth and duration of drawdowns from previous peaks	31.49%	24.93%	+6.56%

Volatility

EDIT vs. PACB - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 31.71% compared to Pacific Biosciences of California, Inc. (PACB) at 19.48%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than PACB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EDIT	PACB	Difference
Volatility (1M) Calculated over the trailing 1-month period	31.71%	19.48%	+12.23%
Volatility (6M) Calculated over the trailing 6-month period	60.26%	66.55%	-6.29%
Volatility (1Y) Calculated over the trailing 1-year period	98.42%	91.97%	+6.45%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.19%	93.91%	-0.72%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.41%	84.47%	-1.06%

Financials